Business
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of
About this update from Dyne Therapeutics, Inc.
[{"type":"text","content":"- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts - - Two posters on myotonic dystrophy type 1 (DM1) focus on health insurance literacy and encore data from ACHIEVE clinical trial - WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that three poster presentations on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) will be presented at the AMCP 2026 Annual Conference being held April 13-16, 2026, in Nashville, TN. “We are excited for a potential DMD launch in the US next year, followed by a potential launch in DM1 in early 2028. As part of the preparations for those two launches, we are engaging with payers now and elucidating how the clinical measures of functional improvement seen in our DELIVER and ACHIEVE trials could translate into meaningful benefits in patients' everyday lives,” said Johanna Friedl-Naderer, chief commercial officer of Dyne. “At AMCP, we are sharing previously reported clinical trial results with information to contextualize the potential benefit of our investigational therapeutics. These data, alongside patient-reported research in DM1, have the potential to ensure that access decisions reflect what matters to patients and the broader community.” Poster Presentations: Zeleciment rostudirsen targets the underlying cause of Duchenne muscular dystrophy (DMD) to enable sustained functional improvement in males with DMD mutations amenable to exon 51 skipping enrolled in the Phase 1/2 DELIVER trialZeleciment basivarsen targets the underlying cause of myotonic dystrophy type 1 (DM1) to enable functional improvement in the Phase 1/2 ACHIEVE trialHealth insurance profile and literacy in myotonic dystrophy type 1 (DM1) The poster on DM1 health insurance and literacy was developed in collaboration with the Myotonic Dystrophy Foundation (MDF) and includes their contributions to the study design and interpretation of results. Additionally, Dyne is supporting a continuing education symposium for managed care professionals through an independent grant. The sym...